Jonathan Duffy

Eric S . Weintraub, M.P.H., James Baggs, Ph.D., Jonathan Duffy, M.D., M.P.H., Claudia Vellozzi, M.D., M.P.H., Edward A. Belongia, M.D., Stephanie Irving, M.H.S., Nicola P. Klein, M.D., Ph.D., Jason M. Glanz, Ph.D., Steven J. Jacobsen, M.D., Ph.D., Allison Naleway, Ph.D., Lisa A. Jackson, M.D., M.P.H., and Frank DeStefano, M.D., M.P.H.: Risk of Intussusception after Monovalent Rotavirus Vaccination The first licensed rotavirus vaccine was withdrawn from the U.S. Market in 1999 due to an increased risk of intussusception.1 Subsequently, two rotavirus vaccines have already been licensed in the United States: RotaTeq in 2006 and Rotarix in 2008.2,3 The two vaccines underwent prelicensure clinical trials involving 60,000 to 70,000 infants each, where no increased risk of intussusception was identified.4,5 Postlicensure monitoring in the Vaccine Security Datalink project hasn’t found a rise in the chance of intussusception after pentavalent rotavirus vaccination.6,7 At the proper time of the study of the pentavalent rotavirus vaccine, too few dosages of the monovalent rotavirus vaccine had been administered to measure the risk of intussusception.

Several additional affected persons subsequently were determined. A total of 19 individuals from 16 households were contained in the present study, showing scientific features suggestive of congenital disorders of glycosylation and an atypical pattern on isoelectric focusing . Approval by a human being subjects committee was attained for all your clinical studies. Written educated consent was attained from all the participants or, in the case of children, from a mother or father or legal guardian. Genetic Studies As the parents of the index family were first cousins and were unaffected, we assumed autosomal recessive inheritance of the disease. We performed homozygosity mapping with DNA from both affected siblings therefore, using Human being1M-Duo BeadChips .